Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash from Operations (2024 - 2025)

Historic Cash from Operations for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to -$6.4 million.

  • Neuphoria Therapeutics' Cash from Operations fell 9149.19% to -$6.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of $100000.0 for FY2025, which is 10068.12% up from last year.
  • As of Q4 2025, Neuphoria Therapeutics' Cash from Operations stood at -$6.4 million, which was down 9149.19% from -$3.8 million recorded in Q3 2025.
  • Over the past 5 years, Neuphoria Therapeutics' Cash from Operations peaked at $11.5 million during Q1 2025, and registered a low of -$6.4 million during Q4 2025.